Compare Amphastar Pharmaceuticals Inc (AMPH) vs Raytheon Technologies Corp (RTX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

RTX trades at $195.93, up 0.37% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026 EPS of $1.78 versus $1.51 expected, highlight robust operational performance. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.03%. The company secured a $515 million U.S. Navy contract for SPY-6 radars (PRNewsWire, 2026-06-03), reinforcing its defense segment strength.

The outlook is positive, driven by defense contract wins and commercial aerospace recovery, but risks include debt levels and geopolitical uncertainties. With a consensus price target of $213.00 (18 buy, 8 hold, 0 sell), the stock offers potential upside, though valuation multiples like a P/E of 36.76 warrant monitoring amid interest rate sensitivity.